ProPark Research Platform

ProPark is designed to deepen our understanding of the biological and clinical diversity within Parkinson’s disease (PD). Using both established and novel quantitative biomarkers, the study tracks differences in disease progression, cognitive and neuropsychiatric symptoms, motor function, treatment response, and adverse drug reactions (ADRs) over a three-year period.

In addition, ProPark includes a comprehensive biobank with uniformly collected longitudinal clinical data, imaging data, wearable data and biological samples. This resource enables the discovery and validation of biomarker profiles, supports advanced data-driven analyses, and helps predict treatment outcomes and individual susceptibility to ADRs.

Researchers can explore and request access to ProPark data and samples via the resources below:

• ProPark Catalog — overview of available data: (https://mica.clinicalresearch.nl/study/propark)
• Study Synopsis — summary of study design and objectives
• Access Procedure — how to request ProPark data or samples (https://proparkinson.nl/wp-content/uploads/2026/02/20250406_ProPark_Clinical_Request_Procedure_V1.1-DEF.pdf)
• Request Form — submit an application (https://proparkinson.nl/wp-content/uploads/2026/02/20220906_Material_Request_Form_ProPark_V1.3L.docx)

We welcome collaborations that advance personalized medicine in Parkinson’s disease.

Contact: propark@lumc.nl, propark@amsterdamumc.nl

Funding: ZonMW, AbbVie B.V., Pharmo Institute NV, Hoffmann-La Roche, H. Lundbeck A/S, Centre for Human Drug Research, Hersenstichting Nederland, Parkinson Vereniging, Stichting Alkemade-Keuls, Ventana Medical Systems, Inc, Stichting Woelse Waard, private